Summary of Conference Call Notes Company Overview - The company discussed is Yidu Technology, a pioneering innovator in the AI healthcare industry with a focus on deepening its expertise over the past decade [1][2]. Key Points and Arguments Industry and Data - Yidu Technology has accumulated 5.5 billion high-quality medical records, covering over 1.1 billion patient visits, which is a significant asset in the Chinese healthcare landscape where data is not typically available post-discharge [1][20]. - The company has developed a comprehensive disease knowledge graph that encompasses all known diseases, supported by various specialized datasets and models [2][19]. Product and Application - The company offers a range of products, including a project management platform and an AI middle platform, which have seen accelerated project orders and implementations since the Chinese New Year, with over 20 projects currently in progress [3][4]. - The AI middle platform integrates multiple open-source models and has already been implemented in several hospitals, demonstrating its practical application in real-world settings [3][10]. Market Position and Competition - Yidu Technology is positioned as a key player in the AI healthcare market, with a belief that the market is still in its early stages and not yet saturated with competition [8][24]. - The company emphasizes that its competitive edge lies in its extensive data accumulation, algorithmic depth, and application scenarios, which are superior to many competitors in the field [20][33]. Financial Performance and Growth - The company anticipates a 10% annual growth in paid services, with a current coverage of 2,800 hospitals, including 105 top-tier hospitals and over 40 regulatory government clients [4][29]. - There is an expectation of improved financial performance and profitability sooner than previously guided, with a focus on enhancing the gross margin through product mix adjustments [29][30]. Collaboration and Partnerships - Yidu Technology has established a deep partnership with Huawei, leveraging their chip technology and exploring further collaboration opportunities in the healthcare sector [6][7]. - The company is also exploring partnerships with various hospitals and government projects, indicating a robust pipeline of collaborative opportunities [9][16]. Challenges and Future Outlook - The company acknowledges challenges in expanding into lower-tier hospitals due to budget constraints but sees potential for future growth as technology costs decrease and demand for intelligent healthcare solutions increases [41][43]. - There is a strong belief that the AI healthcare market will continue to grow, driven by policy support and increasing hospital budgets for technology investments [16][17]. Miscellaneous Insights - The company has noted a significant increase in project budgets from hospitals and government clients, with some budgets rising from millions to tens of millions [16][17]. - Yidu Technology's AI capabilities are designed to assist in various clinical scenarios, including complex cases, showcasing the versatility and depth of its technology [12][36]. Conclusion Yidu Technology is positioned as a leader in the AI healthcare sector, with a strong foundation of data, innovative products, and strategic partnerships. The company is optimistic about future growth, driven by increasing demand for intelligent healthcare solutions and supportive policies.

医渡科技 20250320 摘要 • 医渡科技构建了核心算法引擎——医渡引擎，通过深度挖掘数据价值，截 至 2024 年 9 月 30 日，已处理分析 51 亿份医疗记录，覆盖 10 亿人次，数 据量远超行业平均水平，并深度介入全国前 150 家顶级研究型医院中的 105 家，确保数据质量和算法精准度。 • 公司业务涵盖大数据平台与解决方案（面向医院和政府，项目制，百万至 千万级）、生命科学解决方案（覆盖全球前二十大国际药企中的 16 家，聚 焦核心用户，收入留存比例超 117%）以及健康管理平台与解决方案（覆盖 四省十二市，如北京和深圳），实现全场景覆盖。 • 2025 年春节后，医院对 AI 需求激增，医渡科技的模型调用开源模型并在 东南大学开发专业肝病 AI 医生，获钟南山院士认可。与中山肿瘤医院联合 开发 120 个新应用场景，AI 中台提供五层代码工具链，医生可定制专属 AI agent，30 秒内生成专用场景 AI 助手。 • 医疗数字化效能显著提升，训练资源利用率提高 25%，关键任务准确率提 高 5%-20%，上线周期缩短 50%。千万级别订单增多，但多数医院预算未达 标，公司根据预算调整产品 ...

医渡科技在 AI 医疗行业的业务进展和未来规划是什么？ 医渡科技在 AI 医疗行业深耕近十年，已接入 105 家顶级研究型医院，累计 55 亿份真实医疗数据。这些高质量数据在患者流动和疾病知识图谱方面展现了巨 大价值。公司业务分为三大板块：面向医院和政府的大数据平台与解决方案、 面向药企的生命科学解决方案，以及健康管理平台与解决方案。第一板块主要 通过项目制为医院和监管机构提供智能化平台，如去年推出的 AI 中台及全面数 据库等产品，ASP 从百万级提升至千万级。第二板块围绕药品和器械全生命周 期提供智能化解决方案，涵盖临床开发设计到上市后营销。第三板块则包括慢 病管理、商业险、惠民保险等健康管理服务，目前惠民保业务覆盖四省十二市， • 医渡科技业务涵盖大数据平台与解决方案（面向医院和政府）、生命科学 解决方案（面向药企）以及健康管理平台与解决方案。AI 中台等产品 ASP 提升至千万级，惠民保业务覆盖四省十二市，活跃用户超 2,400 万。 • 医渡科技与华为合作推出深圳一体机，但因医院需求差异大，销售未达预 期。公司采用多种底层技术框架，适配不同芯片，以满足各类医疗场景需 求，并持续优化算法引擎。 • 公 ...

医渡科技 摘要 Q&A 一度科技在 AI 医疗赛道中相比同行的最大优势是什么？公司成立的初衷和目标 是什么？ 在当前的医疗环境中，数据质量是推动大模型功能进化的关键因素。高质量医 疗数据获取难度较大，美国疾病数据可以交易，而中国所有数据都不出院，这 限制了模型性能提升。许多通用类大模型虽然尝试应用于 AI 医疗，但由于缺乏 临床真实数据，对疾病理解有限。一度科技过去十年深耕该赛道，从最早基于 Transformer 架构的小模型发展到现在的大模型，累计了 55 亿份真实医疗数据。 公司未来在研发投入和垂直产品发布节奏方面如何把控？ 目前一度科技的大模型已经能够完全赋能各个业务，但我们仍将持续投入，以 拓展更多应用场景并保持技术领先地位。预计每年研发投入约 8,000 万至 1 亿 元，其中一半用于算力方面，另一半用于人工成本。这种持续高研发和高投入 是必然的，以确保公司在 AI 医疗领域保持竞争优势并推动行业变革。 相较于传统的医疗信息化，医疗 AI 是否可以更直接地为病患带来益处？具体有 哪些方面能够让病患和医生受益？ 过去十年是医疗信息化建设的过程，而未来十年将是向医疗智能化发展的过程。 大模型作为多任务 ...

Summary of Conference Call Records Company and Industry Overview - The conference call discusses a company operating in the healthcare and medical technology sector, focusing on data-driven solutions for hospitals, research institutions, and government agencies. The company emphasizes its advancements in AI and big data applications in healthcare. Core Points and Arguments - The company has provided over 100 sports programs to Chinese sports hospitals, with liabilities exceeding $28 million as of September 30, 2020, indicating financial challenges due to the pandemic [1] - The company has developed a large model for medical applications, achieving extensive use in healthcare, pharmaceuticals, and health insurance sectors, showcasing a decade of experience in creating integrated solutions [2] - A private data model is being constructed for hospital clients, enhancing their data capabilities through customized services, which is crucial for improving regional healthcare services [3] - The large model aids in drug development, enhancing efficiency and safety in clinical trials, indicating a significant role in the pharmaceutical industry [4] - The company provides comprehensive intelligent healthcare services, from health consultations to intelligent medical examinations, improving patient care and operational efficiency [5] - Revenue from the health management platform decreased by 12.4%, attributed to ongoing adjustments in product offerings, while gross margins varied across different segments [6] - Operating expenses as a percentage of revenue have decreased, reflecting improved operational efficiency, with adjusted selling expenses dropping from 27% to 22% [7] - The company maintains a strong cash reserve of approximately RMB 3.74 billion, with a focus on stock buybacks and financial stability [8] - The big data platform generated RMB 134 million in revenue, a 7.5% increase, indicating growth in data-driven solutions for healthcare [9] - The company has participated in over 20 significant medical research projects, enhancing its reputation in clinical research and data analysis [11] - The company has implemented health management solutions in major Chinese cities, contributing to public health initiatives and demonstrating industry leadership [12] - Revenue from biological science solutions decreased by 15%, but the company focuses on high-quality customer engagement and improving client retention rates [13] - The company has made significant advancements in clinical research, completing 368 studies and achieving a 57% increase in pricing for high-demand indications [14] - The integration of AI in health management solutions has improved efficiency, with over 85% of customer interactions being handled by AI, significantly enhancing service delivery [17] - The company aims to provide personalized health management experiences through advanced AI technologies, targeting over 5 million users with tailored health services [18] Other Important but Possibly Overlooked Content - The company emphasizes the importance of data quality and security in healthcare, positioning data as a key driver of the data economy [3] - The integration of AI and big data platforms is seen as a way to enhance the usability of medical data and improve decision-making processes in healthcare settings [10] - The company is focused on maintaining a competitive edge in the healthcare sector by continuously innovating and improving service offerings [9][11]